International Journal of Tumor Therapy

International Journal of Tumor Therapy is an international journal publishing original research aticles, critical reviews, research notes, debate and short reports in all areas of tumor therapy. The journal aims to provide a forum for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in tumor therapy related problems.


Abhishek Srivastava

Post-doctoral Fellow, National Cancer Institute, National Institute of Health, USA

Research Areas

Immunology, Cancer Research, Vaccine

Publications: Journals

[1]  Srivastava AK et al.Identification of lead-regulated genes by suppression subtractive hybridization in the heavy metal accumulator Sesbania drummondii.Planta 225(6): 1353-1365, 2007.
[2]  Sahi SV, Israr M, Srivastava AK et al.Accumulation, speciation and cellular localization of copper in S.drummondii.Chemosphere 67(11): 2257-2266, 2007.
[3]  Srivastava AK et al.Genes induced in response to mercury-ion exposure in heavy metal hyperaccumulator S.drummondii.Environmental Science and Technology 43(3): 843-850, 2009.
[4]  Schabowsky RH, Sharma RK, Madireddi S, Srivastava AK et al.ProtEX technology for the generation of novel therapeutic cancer vaccines.Experimental and Molecular Pathology 86(3): 198-207, 2009.
[5]  Sharma RK, Schabowsky R-H, Srivastava AK et al.4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.Cancer Research 70(10): 3945-54, 2010.
[6]  Sharma RK, Srivastava AK et al.SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.Vaccine 28(36): 5794-802, 2010
[7]  Madireddi S, Schabowsky R-H, Srivastava AK et al.SA-4-1BBL costimulation inhibits conversion of naïve CD4+ T cells into CD4+CD25+FoxP3+ T regulatory cells by production of IFN-γ.PLoS ONE 7(8): e42459, 2012.
[8]  Srivastava AK et al.Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.PLoS One 7(11): e48463, 2012.
[9]  Shirwan H, Sharma RK, Srivastava AK et al.Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines.OncoImmunology 2: e23440, 2013.
[10]  Sharma RK, Yolcu ES, Srivastava AK et al.CD4+ T Cells Play a Critical Role in the Generation of Primary and Memory Antitumor Immune Responses Elicited by SA-4-1BBL and TAA-Based Vaccines in Mouse Tumor Models.PLoS One 8(9), 2013.

Publications: Conferences/Workshops/Symposiums

[1]  Srivastava AK et al.Isolation and characterization of induced genes in response to lead in S.drummondii.Kentucky Academy of Science, 2005.
[2]  Srivastava AK et al.Callus culture of S.drummondii, a medicinally important plant.ASA Southern Branch Annual Meeting, San Antonio, TX, 2005.
[3]  Srivastava AK et al.Growth and copper accumulation in S.drummondii exposed to high concentrations of copper.ASA (Southern Branch), Orlando, FL, 2006.
[4]  Srivastava AK et al.Identification and characterization of lead-responsive genes in S.drummondii by SSH.American Society of Plant Biologist Meeting, Boston, MA, 2006.
[5]  Srivastava AK et al.Costimulation tunes anti-tumor immunity: A novel platform for the development of therapeutic vaccines.Research Louisville, KY, 2009.
[6]  Sharma RK, Srivastava AK et al.A novel vaccine approach for lung cancer immunotherapy.AMLI Annual Meeting, Boston, MA, 2009.
[7]  Srivastava AK et al.Costimulation tunes anti-tumor immunity: A novel platform for the development of therapeutic vaccines.JGBCC, Louisville, KY, 2009.
[8]  Sharma RK, Schabowsky R-H, Srivastava AK et al.SA-4-1BBL as an immune modulator and vehicle to deliver antigens into DCs for generation of robust antitumor therapeutic immune responses.JGBCC Annual Retreat, Louisville, KY, 2009.
[9]  Sharma RK, Srivastava AK et al.Vaccination with survivin as a self TAA and SA-4-1BBL is effective in eradicating established lung carcinomas in CD8+ T cell and NK cell dependent manner.AAI Annual Meeting, Baltimore, MD, 2010.
[10]  Sharma RK, Srivastava AK et al.SA-4-1BBL serves as an effective immunostimulatory component of HPV-16 E7 protein based therapeutic vaccine in a mouse model of cervical cancer.AAI Annual Meeting, Baltimore, MD, 2010.
[11]  Sharma RK, Schabowsky R-H, Srivastava AK et al.SA-4-1BBL costimulatory ligand as an immune modulator and effective vehicle to deliver antigens into DCs for the generation of robust therapeutic antitumor immune responses.AACR Meeting, Washington, DC.2010.
[12]  Sharma RK, Schabowsky R-H, Srivastava AK et al.SA-4-1BBL as an immune modulator and vehicle to deliver antigens into dendritic cells for the generation of robust antitumor immune responses.AAI Annual Meeting, Baltimore, MD, 2010.
[13]  Sharma RK, Srivastava AK et al.4-1BB ligand as a potent and safe adjuvant for the development of T cell based therapeutic cancer vaccines.AMLI, Orlando, FL, 2010.
[14]  Srivastava AK et al.Combination of 4-1BBL and MPL triggers antitumor immunity by promoting favorable Teff/Treg cells ratio.JGBCC Annual Retreat, Louisville, KY, 2010
[15]  Srivastava AK et al.Costimulatory SA-4-1BBL and monophosphoryl A as a novel adjuvant system for the development of cancer vaccines with robust therapeutic efficacy.Accepted for AACR Annual Meeting, Orlando, FL, 2011.

Publications: Books/Book Chapters

[1]  Sharma RK, SrivastavaAK, et al.SA-4-1BBL: A Novel Form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines (in press), Springer-Verlag Wien, 2014